FMW Media's New to The Street TV, a nationally syndicated TV show,
announces episode #345, airing tonight, May 16, 2022, on the Fox
Business Network.
New to The Street’s 345th episode airs tonight,
Monday, May 16, 2022, on the Fox Business Network, features the
following four (4) Companies and their representatives:
1). Tonix Pharmaceuticals,
Inc.'s (NASDAQ: TNXP) interview with Dr. Seth Lederman, MD,
CEO. 2). Sekur Private Data, Ltd.'s (fka
-GlobeX Data, Ltd.) (OTCQX: SWISF) (CSE: SKUR) (FRA: GDT0)
interview with Mr. Alain Ghiai, CEO. 3). Cryptocurrency
– Empire Capital Token's (CRYPTO:
ECC)($ECC) interview with Mr. Lachlan Harnell, Chief
Operations Officer (COO). 4). PetVivo Holdings,
Inc.'s (NASDAQ: PETV) (NASDAQ: PETVW) interview with Mr. John
Lai, CEO / President.
Tonight, New to The Street TV airs Anchor Jane
King’s interview with Tonix Pharmaceuticals, Inc.’s
(NASDAQ: TNXP) CEO, Dr. Seth Lederman, MD. During the show,
Dr. Lederman will explain how the TNXP's fibromyalgia
drug, TNX-102 SL, could help alleviate those with Long COVID
symptoms. Chronic widespread pain, non-restorative sleep, fatigue,
and impaired cognition (brain fog) are symptoms found within 1/3 of
those who have contracted long-covid, similar to those with
fibromyalgia. The U.S. Food and Drug Administration (FDA) recently
cleared TNXP for an Investigational New Drug (IND) application
to support a Phase 2 clinical trial using TNX-102 SL as a potential
treatment for patients with Long COVID. There is an expectation
that millions inflicted with Long COVID across the U.S. and
worldwide will cause a significant burden on health care systems.
In the U.K., 25% apparently cannot work. Dr. Lederman talks
about TNX-102 SL's mid-Phase 3 development for managing
fibromyalgia. Using a dissolvable sublingual tablet to improve
sleep without many side effects is not typical for a sleeping pill.
A good sleep cycle is essential in helping crack the code in
patients with fibromyalgia. Dr. Lederman sees an opportunity to
help many with the TNX- 102 SL.
Mr. Alain Ghiai, CEO at Sekur Private Data,
Ltd. (fka -GlobeX Data, Ltd.) (OTCQX: SWISF)
(CSE: SKUR) (FRA: GDT0) is in-studio at the Nasdaq Marketplace for
tonight’s interview with New to The Street’s T.V. Anchor Jane King.
Alan talks about the Company’s Sekur® solutions, designed to
eliminate cybersecurity issues for individuals and businesses. The
Company's newest encrypted product, "Chat-by-Invite," is a new text
message tool available in the USA, Canada, Australia, New Zealand,
Switzerland, and most of Latin America and Europe, giving
subscribers an utterly private chat. It works when the Sekur
subscriber sends a text message to a recipient, and a link
appears that opens into a private, secure platform hosted in
Switzerland. Essentially, the chat occurs on the Swiss servers
owned and controlled by Sekur Private Data, Ltd. Once the text
message session completes, the text disappears. Hackers won't know
about the transmission because of the highly encrypted military
technology operating behind the product. There is no direct texting
on open-source platforms, making them invulnerable to cybersecurity
breaches. The SekurMail /SekurMessenger, SekurVoice,
SekurProVideo Conference, and other products are available now or
soon. Sekur's "Chat-by-Invite" app is available on iOS and Android;
go to Sekur.com to download it. Subscribers get
cybersecurity protections not available with open-source programs
for reasonable pricing. As an added protection to subscribers,
Sekur Private Data, Ltd operates its internet platforms and
security businesses under the country of Switzerland's very tough
privacy laws.
Anchor Jane King on tonight’s New To the Street TV
talks in-studio at the New York Stock Exchange (NYSE)
with Empire Capital Token's (CRYPTO:
ECC)($ECC) Chief Operations Officer, Mr. Lachlan Harnell. $ECC
is a multi-faceted, yield generation crypto company offering Defi
as a service (Defi 4.0). Lachlan explains how the Company can
assist various blockchain applications using its Defi solutions.
Currently, the Company provides blockchain developers farming,
infrastructure, and other Defi solutions. The main objective at
$ECC is to get more people into the crypto marketplace, making more
users feel confident about crypto transactions and investments. The
$ECC ecosystem offers end-users a platform with a decentralized
focus and offers easy access to crypto solutions for payments on
goods and services. The Company is developing its
"Roundify" app, which offers a Defi access platform on iOS and
Android, expected to roll out later in 2022. Lachlan talks about
$ECC tokenization and the 9% fees generated on the buy-side and the
10% fees on the sell-side transactions, and he breakdowns the use
of proceeds on those fees collected. The Company's treasury will
buy back tokens, raising the $ECC prices that allow an investor a
Rate-of-Return (ROI) on their holdings. Empire Capital Token
removes the need for active management by the user by creating
opportunities to diversify holdings in projects focused on
maximizing staking/farming yields. Users gain the advantage of
broader exposure to the yield farming sector while only needing to
own one token, $ECC. The crypto world is fast-moving with many
advances and changes; Lachlan states, "the industry moves at the
pace of the fastest sprinter." $ECC offers developers and end-user
alike the opportunity to be involved in a cutting-edge Defi entity.
The Company currently operates its ecosystem on the Binance
exchange and Ethereum blockchain. To learn more, go to the
Company's website, https://www.ecc.capital/.
Tonight, New to The Street TV re-airs Mr. John
Lai, CEO / President, PetVivo Holdings,
Inc. (NASDAQ: PETV) (NASDAQ: PETVW),
in-studio Nasdaq Marketplace interview with TV Anchor
Jane King. John provides viewers with his corporate updates. The
injectable patented Spryng with OsteoCushion
Technology treats osteoarthritis and joint afflictions while
providing rehabilitation treatments for horses and dogs and
continues to grow as a reliable treatment. Veterinarians see
continued successes, and dog and horse owners see excellent results
with less pain and more mobilities. Since Spryng mimics cartilage
and lasts about 1-year per injection, competitor products appear to
be no match in cost-benefit comparisons. PETV's corporate studies
continue between Spryng and competitors' products, giving
veterinarians empirical, comprehensive, and marketable data. John
talks about hiring seasoned personnel who became regional managers
so the Company can handle and expand its growth. John announces its
upcoming launch of petvivocares.org, a website dedicated to
donating the Spryng product to charitable non-profit animal rescues
and assistance organizations. "Word of Mouth" and conference
participations seem to be the best form of marketing PETV's Spryng
with OsteoCushion Technology. Soon, PetVivo is rolling out its
feline product for cats with osteoarthritis. This interview segment
initially aired on April 25, 2022.
About PetVivo Holdings, Inc. (NASDAQ:
PETV) (NASDAQ: PETVW):
PetVivo Holdings, Inc. (NASDAQ: PETV)
(NASDAQ: PETVW) is an emerging biomedical device company currently
focused on the manufacturing, commercialization, and licensing of
innovative medical devices and therapeutics for companion animals.
The Company's strategy is to leverage human therapies to treat
companion animals in a capital and time-efficient way. A key
component of this strategy is the accelerated timeline to revenues
for veterinary medical devices that enter the market much earlier
than more stringently regulated pharmaceuticals and biologics.
PetVivo has a pipeline of seventeen products to treat animals and
people. A portfolio of nineteen patents protects the Company's
biomaterials, products, production processes, and use methods. The
Company's lead product Spryng with OsteoCushion Technology, a
veterinarian-administered, intraarticular injection to treat
lameness and other joint-related affliction, including
osteoarthritis, in dogs and horses, is currently available for
commercial sale to veterinarians
- https://petvivo.com/ & https://www.sprynghealth.com/.
About Tonix Pharmaceuticals Holding Corp.
(NASDAQ: TNXP):
Tonix Pharmaceuticals Holding Corp. (NASDAQ:
TNXP) is a clinical-stage biopharmaceutical company focused on
discovering, licensing, acquiring, and developing small molecules
and biologics to treat and prevent human disease and alleviate
suffering. Tonix's portfolio comprises immunology, rare disease,
infectious disease, and central nervous system (CNS) product
candidates. Tonix's immunology portfolio includes biologics to
address organ transplant rejection, autoimmunity, and cancer.
TNX-15001 is a humanized monoclonal antibody targeting CD40-ligand
in development to prevent the prevention of allograft and xenograft
rejection and for the treatment of autoimmune diseases. A Phase 1
study of TNX-1500 is expected to be initiated in the second half of
2022. Tonix's rare disease portfolio includes TNX-29002 for the
treatment of Prader-Willi syndrome. The FDA has granted TNX-2900
Orphan-Drug Designation. Tonix's infectious disease pipeline
consists of a vaccine in development to prevent smallpox and
monkeypox called TNX-8013, next-generation vaccines to prevent
COVID-19, and an antiviral to treat COVID-19. Tonix's lead vaccine
candidates for COVID-19 are TNX-1840 and TNX-18504, live virus
vaccines based on Tonix's recombinant pox vaccine (RPV) platform.
TNX-35005 (sangivamycin, i.v. solution) is a small
molecule antiviral drug to treat acute COVID-19 and is in the
pre-IND stage of development. TNX-102 SL, (cyclobenzaprine HCl
sublingual tablets) is a small molecule drug being developed to
treat Long COVID, a chronic post-acute COVID-19 condition. Tonix
expects to initiate a Phase 2 study in Long COVID in the second
quarter of 2022. The Company's CNS portfolio includes small
molecules and biologics to treat pain, neurologic, psychiatric, and
addiction conditions. Tonix's lead CNS candidate, TNX-102 SL, is in
mid-Phase 3 development for the management of fibromyalgia, with a
new Phase 3 study launched in the second quarter of 2022. Finally,
TNX-13006 is a biologic designed to treat cocaine intoxication that
is expected to start a Phase 2 trial in the second quarter of 2022
- https://www.tonixpharma.com. (1TNX-1500 is an
investigational new biologic at the pre-IND stage of development
and has not been approved for any indication.2TNX-2900 is an
investigational new drug at the pre-IND stage of development and
has not been approved for any indication.3TNX-801 is a live
horsepox virus vaccine for percutaneous administration in
development to protect against smallpox and monkeypox. TNX-801 is
an investigational new biologic and has not been approved for any
indication.4TNX-1840 and TNX-1850 are live horsepox virus vaccines
for percutaneous administration, in development to protect against
COVID-19. TNX-1840 and TNX-1850 are designed to express the
SARS-CoV-2 spike protein from the omicron and BA.2 variants,
respectively. TNX-1840 and TNX-1850 are investigational new
biologics at the pre-IND stage of development and have not been
approved for any indication. 5TNX-3500 is an investigational new
drug at the pre-IND stage of development and has not been approved
for any indication.6TNX-1300 is an investigational new biologic and
has not been approved for any indication.)
About Sekur Private Data
Ltd. (fka- GlobeX Data, Ltd.) (OTCQX:
SWISF) (CSE: SKUR) (FRA: GDT0):
Sekur Private Data, Ltd. (fka- GlobeX
Data, Ltd.) (OTCQX: SWISF) (CSE: SKUR) (FRA:
GDT0) is a Cybersecurity and Internet privacy
provider of Swiss hosted solutions for secure communications and
secure data management. The Company distributes encrypted emails,
secure messengers, secure communication tools, secure cloud-based
storage, disaster recovery, and document management products. The
Company sells and serves consumers, businesses, and governments
worldwide through approved wholesalers, distributors, and
telecommunications companies. Contact Sekur Private Data, Ltd. at
corporate@globexdatagroup.com or
visit https://www.sekurprivatedata.com and https://www.sekur.com.
About Empire Capital
Token (CRYPTO: ECC)
($ECC):
Empire Capital Token (CRYPTO: ECC)
($ECC) is a Defi 3.0 high yield farming & staking smart
contract allowing holders to earn high rewards from a cross-chain
decentralized exchange, EmpireDEX. The Company is a multi-faced
yield generating organization providing Defi-as-a-Service, which is
the synthesis of Farming-as-a-Service, Infrastructure-as-a-Service,
and a suite of development services and tools. Empire Capital is
advancing the boundaries of decentralized finance itself by
encouraging crypto accessibility and normalization through its
groundbreaking app, Roundify. Empire Capital aims to be
the access point for new users to enter the decentralized world
- https://www.ecc.capital/ and https://rua.ecc.capital/.
About FMW Media: FMW Media
operates one of the longest-running US and International sponsored
and Syndicated Nielsen Rated programming TV brands, "New to The
Street" and its blockchain show "Exploring The Block." Since 2009,
these brands have run biographical interview segment shows across
major U.S. Television networks. The TV platforms reach over 540
million homes in the US and international markets. FMW's New to The
Street / Newsmax TV broadcasting platform airs its syndication on
Sundays at 10 -11 AM ET. FMW is also one of the nation's largest
buyers of linear television long and short-form -
https://www.newsmaxtv.com/Shows/New-to-the-Street &
https://www.newtothestreet.com/.
Forward-Looking Statements
Disclaimer:
This press release contains forward-looking
statements within Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934. In
some cases, you can identify forward-looking statements by the
following words: "anticipate," "believe," "continue," "could,"
"estimate," "expect," "intend," "may," "ongoing," "plan,"
"potential," "predict," "project," "should," "will," "would," or
the negative of these terms or other comparable terminology.
However, not all forward-looking statements contain these words.
Forward-looking statements are not a guarantee of future
performance or results and will not necessarily be accurate
indications of the times at which such performance or results are
achieved. This press release should be considered in all filings of
the Companies contained in the Edgar Archives of the Securities and
Exchange Commission at www.sec.gov. CONTACT:
FMW Media Contact: Bryan Johnson +1 (631) 766-7462
Bryan@NewToTheStreet.com
"New to The Street" Business Development Office.
1-516-696-5900 Support@NewtoTheStreet.com
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Sep 2023 to Sep 2024